Search

Your search keyword '"Barta SK"' showing total 121 results

Search Constraints

Start Over You searched for: Author "Barta SK" Remove constraint Author: "Barta SK"
121 results on '"Barta SK"'

Search Results

2. Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation.

3. ASTCT and USCLC Clinical Practice Recommendations for Allogeneic Stem Cell Transplant in Mycosis Fungoides and Sézary Syndrome.

4. Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 study.

5. Evaluation of Ki-67 expression and large cell content as prognostic markers in MZL: a multicenter cohort study.

6. Genomic features of newly diagnosed large B cell lymphoma with or without subsequent disease progression.

7. Prevalence and Prognostication of CD5+ Mature T-Cell Lymphomas.

8. Analysis of Histologic, Immunohistochemical and Genomic Features of Large B Cell Lymphoma Tumors May Predict Response to Polatuzumab Vedotin Based Therapy in Patients With Relapsed/Refractory Disease.

9. Immune-related adverse events associated with mogamulizumab: a comprehensive review of the literature.

10. Immunologic Predictors of Vaccine Responsiveness in Patients With Lymphoma and Chronic Lymphocytic Leukemia.

11. CD5 deletion enhances the antitumor activity of adoptive T cell therapies.

12. The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomas.

13. Bendamustine as Lymphodepletion for Brexucabtagene Autoleucel Therapy of Mantle Cell Lymphoma.

14. Phase II study of the novel antifolate agent pralatrexate in combination with the histone deacetylase inhibitor romidepsin for the treatment of patients with mature T-cell lymphoma.

15. Impact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapy.

16. Subsequent malignant neoplasms in patients previously treated with anti-CD19 CAR T-cell therapy.

17. Targeted Therapies in the Treatment of Mantle Cell Lymphoma.

18. Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucel.

19. CAR T-Cell Immunotherapy in Minority Patients with Lymphoma.

20. T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy.

21. Immunotherapy-resistant acute lymphoblastic leukemia cells exhibit reduced CD19 and CD22 expression and BTK pathway dependency.

23. Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokines.

24. Progress and Pitfalls of Chimeric Antigen Receptor T Cell Immunotherapy against T Cell Malignancies.

25. Real-World Treatment Patterns and Clinical Outcomes With Brentuximab Vedotin or Other Standard Therapies in Patients With Previously Treated Cutaneous T-Cell Lymphoma in the United States.

26. Pralatrexate injection combined with CHOP for treatment of PTCL: results from the Fol-CHOP dose-finding phase 1 trial.

27. Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma.

28. TP53 mutations predict for poor outcomes in patients with newly diagnosed aggressive B-cell lymphomas in the current era.

29. Central Nervous System Relapse in T and NK cell Lymphomas.

30. Impact of circulating lymphoma cells at diagnosis on outcomes in patients with marginal zone lymphoma: a multicenter cohort study.

31. Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort.

32. Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study.

33. 2024 Update: Advances in the risk stratification and management of large B-cell lymphoma.

34. Impact of detectable monoclonal protein at diagnosis on outcomes in marginal zone lymphoma: a multicenter cohort study.

35. SOHO State of the Art Updates and Next Questions | Challenging Cases in Rare T-Cell Lymphomas.

36. Survival Outcomes for Patients with Relapsed/ Refractory Aggressive B Cell Lymphomas Following Receipt of High-Dose Chemotherapy/Autologous Stem Transplantation and/or Chimeric Antigen Receptor-Modified T Cells.

37. Peri-CAR-T practice patterns and survival predictors for all CAR-T patients and post-CAR-T failure in aggressive B-NHL.

38. Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma.

39. Impact of early relapse within 24 months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: A US multisite study.

41. Central Nervous System Progression/Relapse in Mature T- and NK-Cell Lymphomas.

42. Salvage radiotherapy for relapsed/refractory non-Hodgkin lymphoma following CD19 chimeric antigen receptor T-cell (CART) therapy.

43. Postibrutinib relapse outcomes for patients with marginal zone lymphoma.

44. Allogeneic haematopoietic cell transplant in patients with relapsed/refractory anaplastic large cell lymphoma.

45. Mutation analysis performed on tumor biopsies from patients with newly-diagnosed germinal center aggressive B cell lymphomas.

46. Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas.

47. Outcomes of Tisagenlecleucel in Lymphoma Patients With Predominant Management in an Ambulatory Setting.

48. Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study.

50. T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.

Catalog

Books, media, physical & digital resources